These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28561780)

  • 21. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
    Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
    Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
    Gangjee A; Zaware N; Raghavan S; Ihnat M; Shenoy S; Kisliuk RL
    J Med Chem; 2010 Feb; 53(4):1563-78. PubMed ID: 20092323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deciphering the anticancer mechanisms of sunitinib.
    Pal SK; Figlin RA; Yu H
    Cancer Biol Ther; 2010 Oct; 10(7):712-4. PubMed ID: 20716960
    [No Abstract]   [Full Text] [Related]  

  • 24. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
    Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
    Lin B; Song X; Yang D; Bai D; Yao Y; Lu N
    Gene; 2018 May; 654():77-86. PubMed ID: 29454091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
    Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
    Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
    Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A; Zhao Y; Raghavan S; Ihnat MA; Disch BC
    Bioorg Med Chem; 2010 Jul; 18(14):5261-73. PubMed ID: 20558072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
    Gangjee A; Zaware N; Raghavan S; Disch BC; Thorpe JE; Bastian A; Ihnat MA
    Bioorg Med Chem; 2013 Apr; 21(7):1857-64. PubMed ID: 23434139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
    Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
    Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
    Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
    Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
    Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
    FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents.
    Yousefian M; Ghodsi R
    Arch Pharm (Weinheim); 2020 Dec; 353(12):e2000022. PubMed ID: 32885522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.